Related Experiment Video
Updated: Jun 8, 2026

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis
Published on: February 9, 2021
Pharmacotherapy of urolithiasis: evidence from clinical trials
Orson W Moe1, Margaret S Pearle, Khashayar Sakhaee
1University of Texas Southwestern Medical Center, Dallas, Texas 75380, USA. orson.moe@utsouthwestern.edu
Abstract:
Urolithiasis is a worldwide problem with significant health and economic burdens. Medical therapy that alters the course of stone disease has enormous medical and financial impact. Urolithiasis is a final manifestation of a broad range of etiologies and pathogenesis. The modest progress in understanding the pathophysiology has hampered successful development of targeted therapy. Current regimens are based mostly on rational alteration of urinary biochemistry and physical chemistry to lower the risk of precipitation. In terms of pharmacotherapy, there are drugs to successfully improve hypercalciuria, hypocitraturia, aciduria, hyperuricosuria, and hypercystinuria. These agents have been proven to be effective in randomized controlled trials in improving urinary biochemical and physicochemical risk factors, as well as clinical outcomes. Although our current regimens have clearly improved the management and lives of stone formers, there are still clearly identifiable immense voids in the knowledge of pathophysiology of stone disease that can be filled with combined basic science and clinical studies.
Insights
Urolithiasis, a global health issue, is managed with therapies targeting urinary biochemistry to prevent stone formation. While effective, further research into stone disease pathophysiology is needed for improved treatments.
Area of Science:
- Nephrology
- Urology
- Biochemistry
Background:
- Urolithiasis presents a significant global health and economic challenge.
- Understanding the complex pathophysiology of stone disease remains limited, hindering targeted therapeutic development.
- Current management strategies focus on altering urinary biochemistry and physical chemistry to reduce stone precipitation.
Purpose of the Study:
- To review current medical therapies for urolithiasis.
- To highlight the impact of pharmacotherapy on urinary risk factors.
- To identify knowledge gaps in stone disease pathophysiology.
Main Methods:
- Review of existing literature on urolithiasis management.
- Analysis of pharmacotherapy effectiveness in randomized controlled trials.
- Discussion of biochemical and physicochemical risk factors for stone formation.
Main Results:
- Pharmacotherapies effectively address hypercalciuria, hypocitraturia, aciduria, hyperuricosuria, and hypercystinuria.
- Randomized controlled trials demonstrate the efficacy of these agents in improving risk factors and clinical outcomes.
- Current regimens have improved the management and quality of life for individuals with urolithiasis.
Conclusions:
- Medical therapies targeting urinary biochemistry are effective in managing urolithiasis.
- Significant gaps in understanding the pathophysiology of stone disease persist.
- Combined basic science and clinical studies are essential to advance knowledge and develop novel targeted therapies.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Calculi V: Nursing Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care